Abstract: Provided herein are methods of preparing a high concentration, liquid composition comprising an oligonucleotide compound. In exemplary embodiments, the method comprises exchanging by diafiltration an oligonucleotide compound in a starting solution into a diafiltration (DF) solution to obtain an intermediate solution, wherein the concentration of the oligonucleotide compound in the starting solution is 140 mg/mL or less and the DF solution comprises one or more salts, and concentrating by ultrafiltration the oligonucleotide compound in the intermediate solution to obtain a high concentration, liquid composition, wherein the concentration of the oligonucleotide compound in the high concentration, liquid composition is greater than about 150 mg/mL.

Abstract: The disclosure provides formulations comprising sotorasib (1), a diluent, a disintegrant and a lubricant.

Abstract: The invention disclosed herein is a novel media milling process performed in an atmosphere of propellants(s) utilizing a resonant acoustic mixing (RAM) device. The process is utilized to reduce the particle size of API (optionally including excipients) to a respirable size range while ensuring the retention of the crystallinity of the milled API.

Abstract: Described herein is a process for preparing agglomerates comprising: (i) providing a dry powder mixture of one, two, or three active pharmaceutical agent(s), and at least one excipient; and (ii) applying acoustic energy to said dry powder mixture to form agglomerates.

Abstract: Various embodiments of the present invention provide for an agglomerate comprising at least one active pharmaceutical agent and at least one excipient; wherein at least about ninety percent of the at least one active pharmaceutical agent have a particle size of less than about 2 ?m.

Abstract: Several embodiments of the present invention provide for an agglomerate useful for an agglomerate based dry powder inhaler comprising at least one active pharmaceutical agent, at least one additional functional excipient and at least one excipient, such as a binder. Useful at least one additional functional excipients include but are not limited to magnesium stearate, colloidal silica, silicon dioxide, sucrose stearate, L-leucine and combinations thereof.